Trial Profile
Omalizumab in the treatment of allergic bronchopulmonary aspergillosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Therapeutic Use
- 16 Nov 2015 New trial record
- 01 Nov 2015 Results published in the Allergy and Asthma Proceedings